4.8 Article

An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma

期刊

MOLECULAR CELL
卷 82, 期 16, 页码 3030-+

出版社

CELL PRESS
DOI: 10.1016/j.molcel.2022.06.003

关键词

-

资金

  1. Cancer Prevention and Research Institute of Texas (CPRIT) [RR190058]
  2. Department of De- fense Kidney Cancer Research Program Idea Development Award [W81XWH1910813]
  3. National Cancer Institute [R01CA211732, P50CA196516]
  4. NCI [R37CA226771]
  5. Welch Foundation Award [I-1879]
  6. UT Presidential Scholar Award
  7. National Cancer Insti- tute [P30 CA142543]
  8. CPRIT [RP180770]
  9. U.S. Department of Defense (DOD) [W81XWH1910813] Funding Source: U.S. Department of Defense (DOD)

向作者/读者索取更多资源

The JMJD6-DGAT1 axis plays a critical role in ccRCC tumor development. JMJD6 interacts with RBM39 and co-occupies the DGAT1 gene promoter to induce DGAT1 expression. Silencing JMJD6 reduces DGAT1 expression, leading to inhibition of lipid droplet formation and tumorigenesis. Pharmacological inhibition of DGAT1 suppresses lipid droplet formation and ccRCC tumorigenesis.
Characterized by intracellular lipid droplet accumulation, clear cell renal cell carcinoma (ccRCC) is resistant to cytotoxic chemotherapy and is a lethal disease. Through an unbiased siRNA screen of 2-oxoglutarate (2-OG)-dependent enzymes, which play a critical role in tumorigenesis, we identified Jumonji domain -contain-ing 6 (JMJD6) as an essential gene for ccRCC tumor development. The downregulation of JMJD6 abolished ccRCC colony formation in vitro and inhibited orthotopic tumor growth in vivo. Integrated ChIP-seq and RNA-seq analyses uncovered diacylglycerol O-acyltransferase 1 (DGAT1) as a critical JMJD6 effector. Mechanis-tically, JMJD6 interacted with RBM39 and co-occupied DGAT1 gene promoter with H3K4me3 to induce DGAT1 expression. JMJD6 silencing reduced DGAT1, leading to decreased lipid droplet formation and tumorigenesis. The pharmacological inhibition (or depletion) of DGAT1 inhibited lipid droplet formation in vitro and ccRCC tumorigenesis in vivo. Thus, the JMJD6-DGAT1 axis represents a potential new therapeu-tic target for ccRCC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据